new glp 1 drug retatrutide GLP-1 obesity drug, retatrutide, shows added benefits Retatrutide Weight Loss | GLP-1,

doi: 10.3389/fendo.2025.1570603 Received 03 February 2025 Accepted 29 April 2025 Published 21 May 2025 Volume 16 - 2025 Edited by Jared Rutter, The University of Utah, United States Reviewed by Steven Patterson, Glasgow Caledonian University, United Kingdom Elena Jimenez Marti, University of Valencia, Spain Nigel Irwin, Ulster University, United Kingdom Updates Copyright 2025 Koefoed-Hansen, Helsted, Kizilkaya, Lund, Rosenkilde and Gasbjerg

2023;133:e167700

Lixisenatide in patients with type 2 diabetes and Acute Coronary Syndrome

However, GLP-1 has a very short half-life of about 1.5 minutes and is rapidly suppressed by an enzyme called dipeptidyl peptidase-4 (DPP-4)

Five RCTs evaluating liraglutide reported cases of thyroid cancer (9 liraglutide vs